The present work describes the development
of an improved synthesis
of the active pharmaceutical ingredient (API) dimethyl fumarate. The
use of continuous flow technology and the newly developed methylation
conditions solve some of the issues of previous commercial production
strategies, e.g., reaching complete
conversion and avoiding the formation of toxic impurities. The optimization
was carried out using the design of experiment approach and afforded
a very efficient, sustainable process, suitable for the industrial
application.